| Date | Title | Description |
| 18.06.2024 | Clover Announces Positive Preliminary Phase Ⅰ Results for Bivalent RSV Vaccine Candidate SCB-1019 in Older Adults | -- Bivalent SCB-1019 significantly boosted RSV-A and RSV-B neutralizing antibody titers in older adults up to approximately 7,900 IU/mL (up to 8-fold increase) and approximately 46,700 IU/mL (up to 11-fold increase), respectively --
-- Favo... |
| 25.04.2024 | 1st Quarter Results | 1st Quarter Results
Thu, Apr 25, 2024 08:00 CET Report this content
AstraZeneca
25 April 2024
Q1 2024 results
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Revenue and EPS summary
Q1 2024 % ... |
| 08.04.2024 | Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort | -- Bivalent SCB-1019 significantly boosted RSV-A and RSV-B neutralization titers to approximately 6,600 IU/mL (6.4-fold increase) and approximately 46,000 IU/mL (12-fold increase), respectively --
-- Preliminary Phase I data in target older... |
| 19.02.2024 | AstraZeneca completes acquisition of Icosavax | AstraZeneca completes acquisition of Icosavax
Mon, Feb 19, 2024 16:20 CET Report this content
19 February 2024
Acquisition of Icosavax Completed
AstraZeneca announced today the successful completion of the acquisition of Icosavax, Inc., a U... |
| 12.12.2023 | AstraZeneca to acquire Icosavax | AstraZeneca to acquire Icosavax
Tue, Dec 12, 2023 08:05 CET Report this content
News Release
Regulatory News Service
12 December 2023
AstraZeneca to acquire Icosavax, including potential first-in-class RSV and hMPV combination vaccine with ... |
| 22.05.2023 | Icosavax Announces $67.8 Million Registered Direct Offering of Common Stock | - |
| 22.05.2023 | Icosavax Announces $67.8 Million Registered Direct Offering of Common Stock | - |
| 01.08.2021 | Icosavax’s $182M IPO haul is key for RSV, but eyes are on its Covid vaccine too | The field of companies pursuing a vaccine for respiratory syncytial virus (RSV) includes several pharmaceutical giants with plenty of resources and cash to pour into research. The scientists at four-year-old Icosavax believes their company’... |
| 07.07.2021 | Seattle-based Icosavax, which is developing COVID-19 vaccines, files for IPO 4 years after launch | Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design. (Icosavax Photo)
Seattle-based Icosavax has filed to go public via an IPO, just four years after it launched ou... |
| 07.04.2021 | Univ. of Wash.-spinout Icosavax raises $100M to fund vaccine development technology | Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design. (Icosavax Photo)
New funding: At a moment when vaccines are on everyone’s mind, a Seattle-based biotech company... |
| 07.04.2021 | Icosavax lands $100M to take its virus-like particle vaccines into clinical trials | The Seattle-based biotech is developing vaccines based on virus-like particles (VLPs), proteins that resemble viruses. Naturally occurring VLPs are already the basis of commercially available vaccines for human papillomavirus and hepatitis ... |
| 07.04.2021 | Icosavax Inks $100M Series B Funding Round |
SEATTLE, WA, Icosavax today announced the close of a $100 million Series B Financing.
>> Click here for more funding data on Icosavax
>> To export Icosavax funding data to PDF and Excel, click here
The round was led by RA... |
| 07.04.2021 | Icosavax raises $100M to take RSV, COVID-19 vaccines into clinic | Icosavax has raised $100 million to study viruslike particle (VLP) vaccines against diseases including respiratory syncytial virus (RSV) and COVID-19. The series B round equips Icosavax to take two assets into clinical trials this year.
Sea... |
| 07.04.2021 | Icosavax raises $100M to take RSV, COVID-19 vaccines into clinic | Icosavax has raised $100 million to study viruslike particle (VLP) vaccines against diseases including respiratory syncytial virus (RSV) and COVID-19. The series B round equips Icosavax to take two assets into clinical trials this year.
Ico... |
| 07.04.2021 | Icosavax Closes $100M Series B Financing | Icosavax, Inc., a Seattle, WA-based vaccine development company, closed a $100m Series B financing.
The round was led by RA Capital Management with participation from Janus Henderson Investors, Perceptive Advisors, Viking Global Investors, ... |
| 07.04.2021 | Daily funding roundup - April 7th, 2020 | CaptivateIQ raised $46M; Snorkel AI landed $35M; Pathlight secured $25M; Pica8 picks up $20M
MasterClass: MasterClass is a San Francisco-based company that sells subscriptions to online courses taught by experts. MasterClass is raising new ... |
| 19.03.2021 | Icosavax, Inc. announced that it has received $99.729694 million in funding from a group of investors | Icosavax, Inc. announced a private placement of 32,958,612 Series B-1 Preferred Stock at a price of $2.82172 for gross proceeds of $92,999,974.65264 and 2,805,850 Series B-2 Preferred Stock at a price of $2.39846 for gross proceeds of $6,72... |
| 09.03.2020 | To develop a coronavirus vaccine, synthetic biologists try to outdo nature | Even as companies rush to develop and test vaccines against the new coronavirus, the Bill and Melinda Gates Foundation and the National Institutes of Health are betting that scientists can do even better than what’s now in the pipeline.
If,... |
| 03.10.2019 | Icosavax raises $51M to take VLP RSV vaccine into humans
W h i t e p a p e r
Vital Precision for Cost Reduction, QA, and Regulatory Compliance | Icosavax has raised a $51 million series A round to take respiratory syncytial virus (RSV) vaccine IVX-121 through phase 1b in older adults. The vaccine is built on computationally designed self-assembling viruslike particle (VLP) technolog... |
| 03.10.2019 | Univ. of Washington spinout Icosavax raises $51M to fight viruses with computer-designed vaccines | Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design. (Icosavax Photo)
Seattle-based biotech startup Icosavax today scored $51 million in funding to create vaccines ... |
| 03.10.2019 | Icosavax Raises $51M in Series A Financing | Icosavax, Inc., a Seattle, WA-based company developing vaccines against infectious diseases, launched with $5m in Series A financing.
The round was led by Qiming Venture Partners USA with participation from Adams Street Partners, Sanofi Ven... |
| 03.10.2019 | Icosavax Announces $51M Series A Round |
SEATTLE, WA, Icosavax today announced the launch of the company with a $51 million Series A financing.
>> Click here for more funding data on Icosavax
>> To export Icosavax funding data to PDF and Excel, click here
The ro... |
| 03.10.2019 | Icosavax raises $51M to take VLP RSV vaccine into humans | Icosavax has raised a $51 million series A round to take respiratory syncytial virus (RSV) vaccine IVX-121 through phase 1b in older adults. The vaccine is built on computationally designed self-assembling viruslike particle (VLP) technolog... |
| 03.10.2019 | Icosavax nabs $51M as synthetic virus heads toward clinic | A new biotech is using an artificial virus-like particle to try to vaccinate against the respiratory syncytial virus (RSV), a flu-like disease for which no vaccination or cure exists.
Icosavax launches with a $51 millio... |
| - | Icosavax’s $182M IPO haul is key for RSV, but eyes are on its Covid vaccine too | The field of companies pursuing a vaccine for respiratory syncytial virus (RSV) includes several pharmaceutical giants with plenty of resources and cash to pour into research. The scientists at four-year-old Icosavax believe their company’s... |
| - | Icosavax lands $100M to take its virus-like particle vaccines into clinical trials | Icosavax has drawn up clinical trial plans for its new type of vaccine in a strategy to commence tests of multiple programs, including a Covid-19 candidate. But really, the startup is following a path blazed by Mother Nature.
The Seattle-ba... |
